Brain tumors are among the most lethal cancers, with limited success from emerging immunotherapies, largely due to the reshaping of the surrounding tumor microenvironment to promote tumor growth, invasion and immune evasion. Astrocytes are abundant glial cells of the central nervous system (CNS) that can activate distinct molecular programs to support glioblastoma and brain metastases.
Although astrocytes are central regulators of the immune response in the CNS, their role in shaping tumor immunity remains relatively underexplored. Emerging evidence indicates that reactive astrocytes are important drivers of local immunosuppression, which constitutes a major barrier to the development of efficacious immunotherapies for brain tumors.
In this Review, we examine astrocyte reprogramming by tumor-derived signals, its effect on tumor immunity, and emerging strategies to modulate astrocyte responses and immunotherapy outcomes. Access to this article via Institution of Civil Engineers Library is not available.
Andersen, B. M.
et al. Barcoded viral tracing identifies immunosuppressive astrocyte–glioma interactions.
Nature 644 , 1097–1106 (2025). Faust Akl, C.
et al. Glioblastoma-instructed astrocytes suppress tumour-specific T cell immunity.
Nature 643 , 219–229 (2025). Perelroizen, R.
et al.
Nature Immunology published a clinical update in Infectious Disease on 23 Apr 2026.
The item focuses on Astrocyte-driven immunosuppression in the brain tumor microenvironment.
Review the original article for the full source wording and details.